BMO Capital initiated coverage of Omada Health (OMDA) with an Outperform rating and $27 price target A large under-penetrated total addressable market, recent roll-out of an enhanced GLP-1 companion program, AI investments, and increasing cross-selling momentum provides significant runway for continued revenue growth of 20%+ and expanding margins, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health Reports Strong Growth and Innovation
- Omada Health price target raised to $32 from $30 at Morgan Stanley
- Omada Health price target raised to $28 from $27 at Evercore ISI
- Omada Health, Inc.: Strong Revenue Momentum and Strategic Partnerships Drive Buy Rating
- Omada Health, Inc.: Strong Market Position and Growth Potential Drive Buy Rating